Brand Versus Non-Brand Search: The Metric Most Diligence Misses
This is Dimension 2 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
Part 2 of 7 — The Patient Marketing Diligence (PMD) Framework
A practice can show a strong ROAS and a falling cost per patient while its paid marketing is doing almost nothing.
That sounds like a contradiction, but it isn’t. It’s what happens when a target’s advertising is mostly capturing brand versus non-brand search, meaning the ads are running against people who were already searching for the practice by name, rather than generating demand that wouldn’t have existed otherwise. The metrics look excellent. The marketing engine behind them may not be doing much real work at all.
That’s Dimension 2 of the Patient Marketing Diligence framework, and it’s arguably the single clearest test in the entire framework for whether a target’s growth is structural or borrowed.
What Brand Versus Non-Brand Search Actually Means
Brand search is anyone searching for the practice by name, a close misspelling of it, or clicking a retargeting ad after already visiting the site. Non-brand search is everything else: someone searching by condition, procedure, or category, the kind of query that represents genuine new demand entering the funnel for the first time.
The distinction matters because brand search converts extremely well and extremely cheaply almost by definition. Someone typing the practice’s name into Google has usually already decided to go there. Paying to show them an ad isn’t creating a patient, it’s paying to stand in front of a door that was already about to open.
Non-brand search is the opposite. It’s harder to win, more expensive, and far more reflective of whether the marketing program is actually generating incremental patients rather than intercepting ones who were coming regardless.
Why This Is the Metric That Exposes Inflated Growth Stories
A practice preparing for a sale wants clean numbers. Brand search delivers clean numbers almost automatically, since it’s cheap and high-converting by nature. A seller doesn’t need to do anything sophisticated to post a strong ROAS if a large share of paid conversions are coming from brand campaigns.
This is exactly why brand versus non-brand search deserves more attention in diligence than it typically gets. A buyer who only checks headline ROAS or CAC can walk straight into overpaying for demand that was never actually created by the acquisition engine, and that would keep showing up in organic search or direct traffic even if the entire paid program disappeared the day after close.
How to Actually Pull This Number
This isn’t something you can read off a dashboard summary. It requires going into the Search Terms report inside Google Ads and classifying queries individually, the practice’s name, common misspellings, and branded variants on one side, everything else on the other. Campaign names aren’t reliable for this. A campaign labeled “Brand” can still contain non-brand queries if match types are loose, and a campaign labeled something generic can quietly be dominated by branded traffic. Classification has to happen at the query level, not the campaign level.
Match type matters here too. Brand campaigns running on broad or phrase match will often pull in adjacent non-brand queries, which inflates what looks like brand performance and can misrepresent the split if you’re not checking the actual search terms underneath.
One more check worth running: pull organic and direct traffic trends from the same period, side by side with paid conversions. If paid conversions have been climbing while organic and direct traffic stayed flat or declined, that’s a real signal of channel substitution, meaning the growth didn’t come from new demand, it came from paid media taking credit for people who would have found the practice anyway.
And a note on retargeting specifically: it doesn’t look like brand search, but functionally it behaves the same way. Someone who already visited the site and gets served a retargeting ad isn’t new demand either. For this dimension, retargeting and remarketing campaigns should be counted alongside brand, not lumped in with genuine prospecting.
Scoring It
The framework scores this dimension based on non-brand share of total paid conversions, from 65% or higher at the excellent end, down to below 20%, or a target that can’t produce the split at all, at the bottom.
The two Hard Flags here are worth knowing going in. First, if management cannot produce a brand versus non-brand split, or won’t allow it to be independently verified through account access, that itself is a finding, not just a data gap. Second, if reported growth in paid conversions lines up with a period of flat or declining organic and direct traffic, that’s strong evidence of channel substitution rather than real growth, and should be treated as a disqualifying pattern rather than a footnote.
Why It Matters for the Deal
This dimension is often the one most likely to actually move a valuation conversation. Growth built on real non-brand demand generation is a genuine, transferable capability, the kind of thing that justifies paying for the marketing function as part of the platform’s value. Growth built on brand-term capture is closer to a bolt-on than an engine. It will look identical in the reported numbers whether or not the paid program exists at all, which means a buyer relying on headline metrics alone risks paying a growth multiple for demand that costs nothing to keep and was never actually created by what they’re acquiring.
This is Dimension 2 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
Get the full framework: all 7 dimensions, complete scoring criteria, evidence sourcing, and red flag triggers, delivered free.